NASDAQ$JANX
Janux Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Janux transitioned to a clinical-stage company by dosing the first patient with PSMA-TRACTr and advancing its pipeline utilizing its novel TRACTr and TRACIr platforms.
Janux Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022. The company's lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients and Janux received FDA clearance for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008).
- Lead program PSMA-TRACTr (JANX007) continues to enroll in first-in-human Phase 1 clinical trial in prostate cancer patients.
- Janux received U.S. Food and Drug Administration (FDA) clearance for an IND application for EGFR-TRACTr (JANX008).
- PD-L1xCD28 TRACIr (JANX009) on-track for an IND submission in 2023.
- TROP2-TRACTr evaluations to support development candidate selection are ongoing.
Headline financials
Revenue & EPS history
Janux · Revenue · Quarterly
$2.85M
Revenue by segment
Janux · $1.06M total across 1 segment · Q2 2023
- Collaboration revenue$1.06M-55.3%100.0%
Forward guidance
Janux anticipates providing an interim clinical update from the PSMA-TRACTr (JANX007) trial in the second half of 2023. In addition, Janux expects to select a development candidate for its TROP2-TRACTr in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.6%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-5.5%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-11.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | -1.4% | -8.8% | |
| Q4 2025 | -1.4% | +4.0% | -4.5% | |
| Q3 2025 | +3.9% | +4.8% | -40.1% | |
| Q1 2025 | -0.8% | +3.8% | -2.8% | |
| Q4 2024 | +2.7% | -1.6% | -9.1% | |
| Q3 2024 | -1.9% | -2.9% | +17.6% | |
| Q2 2024 | -1.1% | -0.8% | +11.8% | |
| Q1 2024 | -11.0% | -21.3% | -31.5% | |
| Q4 2023 | -1.6% | -1.7% | -13.5% | |
| Q3 2023 | +5.9% | -3.4% | +50.7% | |
| Q2 2023 | +5.1% | +4.3% | -11.6% | |
| Q1 2023 | +1.1% | -7.0% | -3.5% | |
| Q4 2022 | -2.5% | -4.7% | -4.9% | |
| Q3 2022 | +14.6% | +5.3% | -9.8% | |
| Q2 2022 | +1.0% | -4.9% | -3.2% | |
| Q1 2022 | +6.1% | +13.7% | +10.0% | |
| Q4 2021 | -6.0% | -3.5% | -17.1% | |
| Q3 2021 | -1.6% | -7.4% | -23.9% | |
| Q2 2021 | -1.0% | -3.8% | -9.9% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro